Semaglutide Cost in 2026: Every Price Point Compared

Summary: Brand semaglutide list prices in 2026 land between $968 and $1349 per month, but almost nobody pays sticker. The cheapest legal paths run from $25 with commercial insurance to $199 for NovoCare's starter month, with telehealth compounded options narrowing fast as the FDA shortage closes.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: brand semaglutide in 2026 lists between $968 and $1349 per month, depending on which version you take. Ozempic is roughly $968, Wegovy is roughly $1349, and Rybelsus oral tablets run about $1029. Most people pay far less. Commercial insurance with a Wegovy or Ozempic savings card cuts the bill to $0 to $225 per month. Novo Nordisk's NovoCare self-pay program ships Wegovy for $499 per month cash, with a $199 first-month starter price. Compounded semaglutide from telehealth clinics still sits between $149 and $400 per month in 2026, but access is narrowing fast since the FDA closed the shortage ^[1][2][3].

This page lines up every price point in one place. If you only want the cheapest legal path for your situation, skip to the recommendation tree.

Brand list prices in 2026

The three FDA-approved semaglutide products are made by Novo Nordisk. They share a molecule and a manufacturing process, but the FDA approved them for different indications at different doses, which is why their prices diverge.

These are wholesale acquisition costs, the published list prices that pharmacies use as a starting point. The figure on your pharmacy receipt before any insurance adjustment or coupon is almost always within a few dollars of the list price ^[4].

Wegovy costs more than Ozempic because the FDA approved it at higher maintenance doses (up to 2.4 mg weekly versus 2.0 mg for Ozempic) and labeled it for obesity, a market where insurers have historically resisted coverage and Novo Nordisk has had less pricing pressure from payers. Rybelsus is priced between them because the daily oral formulation requires far more semaglutide per month to achieve the same systemic exposure as the weekly injection.

What insurance actually pays

Commercial insurance coverage for semaglutide depends entirely on the indication on your prescription and your plan's formulary.

Ozempic for type 2 diabetes

Ozempic is covered by most commercial plans, Medicare Part D, and most state Medicaid programs when prescribed for type 2 diabetes. Copays typically run $25 to $100 per month for commercial plans and $0 to $50 for Medicaid. Novo Nordisk's Ozempic savings card brings the commercial copay down to $25 per month for up to 24 months, with a $150 maximum savings per fill ^[2]. People without commercial insurance, including anyone on Medicare or Medicaid, are not eligible for that card.

Wegovy for weight loss

This is where coverage gets messy. Wegovy is approved for chronic weight management, and most commercial plans either exclude weight-loss drugs entirely or require prior authorization with documented BMI thresholds, comorbidities, and prior failed weight-loss attempts. When Wegovy is covered, copays land between $25 and $300 per month. The Wegovy savings card knocks up to $225 off the monthly copay for commercial insurance holders, with a $1800 annual maximum ^[1].

Self-funded employer plans set their own rules. Some of the largest US employers, including the federal government's FEHB program, expanded Wegovy coverage in 2025 after the SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiac events. Other employers tightened restrictions or dropped weight-loss coverage entirely to control costs. There is no national pattern. Call your plan.

Wegovy for cardiovascular risk reduction

In 2024 the FDA expanded Wegovy's label to include reducing major adverse cardiovascular events in adults with established heart disease and either obesity or overweight. This unlocked coverage from plans that exclude weight-loss drugs but cover cardiovascular ones, including Medicare Part D. If you have documented atherosclerotic cardiovascular disease and a BMI of 27 or higher, your prescriber can write Wegovy under the CV indication, and Medicare Part D plans must cover it ^[5]. Part D copays for Wegovy under this indication typically range from $50 to $200 per month depending on the plan's tier placement.

Rybelsus

Rybelsus is covered similarly to Ozempic, since it shares the type 2 diabetes indication. Commercial copays run $25 to $100 with the savings card.

NovoCare: the manufacturer's cash-pay program

NovoCare is Novo Nordisk's direct-to-patient pharmacy launched in 2025. It exists because the brand was losing market share to compounded semaglutide and wanted to offer a cash price that competed.

The $499 monthly rate applies to all five Wegovy dose strengths and includes home delivery. The $199 starter month is one time per patient. You qualify if your commercial insurance does not cover Wegovy, or if you have no prescription drug coverage at all. Medicare and Medicaid beneficiaries are not eligible for the cash-pay rate; they use their plan's pharmacy benefit ^[1].

NovoCare does not sell Ozempic at a cash discount. The $968 list price stands for Ozempic if you have no coverage, although GoodRx and other discount cards can shave 10 to 20% off that figure at retail pharmacies.

The savings card path

If you have commercial insurance, this is almost always the cheapest legal route.

• Ozempic savings card: $25 per month copay for up to 24 months. Maximum savings of $150 per fill ^[2]. Activates online at ozempic.com.
• Wegovy savings card: up to $225 off the monthly copay for commercial plans that cover Wegovy. $1800 annual cap ^[1]. For commercial plans that do not cover Wegovy, the card is not usable; use NovoCare instead.
• Rybelsus savings card: similar $10 to $25 copay structure for commercial holders, with a $300 maximum savings per fill.

You cannot stack a savings card with Medicare, Medicaid, Tricare, VA, or any other government insurance. Federal law prohibits it. If you are on a government plan, your copay is set by the plan's formulary tier.

Medicare and Medicaid in 2026

Medicare Part D covers Ozempic and Rybelsus for type 2 diabetes. Copays vary by plan and tier but typically run $0 to $100 per month. Catastrophic coverage now caps annual out-of-pocket Part D spending at $2000 per year as of the Inflation Reduction Act's 2025 phase-in, so even high-cost months stop counting once you hit that cap ^[5].

Wegovy coverage under Medicare Part D is limited to the cardiovascular risk indication. Medicare statute prohibits Part D coverage of drugs prescribed for weight loss alone, but the 2024 label expansion let plans cover Wegovy when prescribed for established cardiovascular disease plus elevated BMI. Most Part D plans have added Wegovy to their formularies under that indication for 2026.

Medicaid coverage of semaglutide is state by state. All states cover Ozempic and Rybelsus for type 2 diabetes. About a dozen states cover Wegovy for weight loss, often with strict prior authorization. Check your state Medicaid drug formulary directly; the list changes year to year.

Compounded semaglutide: what changed in 2026

For two years, compounded semaglutide from 503A and 503B pharmacies was the dominant cash-pay channel. Prices ran $200 to $400 per month, and telehealth clinics like Hims, Ro, Mochi, Henry Meds, and dozens of smaller operators built large books of business on it. That window is closing.

The FDA officially resolved the semaglutide injection shortage in 2025 ^[3]. Under federal law, compounding pharmacies are not allowed to produce essentially copy versions of an FDA-approved drug except during a declared shortage or when individual patients require a documented clinical modification (a different dose, an excluded ingredient, a different formulation). With the shortage closed, the legal basis for mass-market compounded semaglutide narrowed. 503B outsourcing facilities had a wind-down period to use existing stock, and most stopped producing standard-formulation semaglutide by mid-2025. 503A pharmacies can still compound for individual patients with documented clinical need, but the volume is a fraction of what it was.

What this means in practice for 2026:

• Compounded semaglutide is still legally available, but only as patient-specific compounded preparations with a clinical justification (allergy to an excipient, unusual dose, combination formulation with B12 or NAD).
• Standard-formulation compounded semaglutide from a national telehealth provider is no longer permitted under FDA enforcement policy.
• Cash prices for clinically justified compounding still run $200 to $400 per month, but availability depends on the prescriber's documentation and the pharmacy's policies.
• Any website still selling generic-strength compounded semaglutide at low monthly prices without a clinical justification is operating outside FDA guidance. Buyer beware.

If you were on compounded semaglutide in 2024 or 2025 and your telehealth provider has not transitioned you, expect a forced switch to brand Wegovy via NovoCare or Ozempic via insurance during your next refill cycle.

Telehealth subscription pricing in 2026

Telehealth providers are still in the mix, but most have pivoted from selling compounded product to handling the prescribing and shipping logistics for brand Wegovy and Ozempic. Pricing varies by provider and includes the medication, the consultation, and shipping.

The economics for cash-pay patients shifted in 2025. Before NovoCare launched, telehealth was the only realistic way to get semaglutide for under $500 a month without insurance. Now that Novo Nordisk sells Wegovy direct for $499, the gap between telehealth compounded ($300 ish) and brand ($499) closed enough that many patients moved to brand. Telehealth providers compensate by bundling clinical care, dietitian access, and labs.

Why semaglutide is so expensive in the first place

A short answer to a question most people ask: semaglutide manufacturing costs are estimated at $5 to $20 per month of supply at the active ingredient level. The retail price is a function of US drug pricing structure, not production cost.

The three factors that drive the list price:

1. Patent protection. Novo Nordisk holds composition-of-matter and formulation patents on semaglutide that extend into the early 2030s. No generic competition is permitted in the US until those patents expire or are invalidated.
2. Lack of price negotiation. US Medicare did not negotiate semaglutide prices until 2025, and even then negotiations apply only to a handful of selected drugs. Wegovy and Ozempic were added to the Medicare negotiation list for 2027 implementation, so list prices may drop then.
3. Demand-driven pricing. The clinical results in SELECT and STEP trials drove demand that outstrips supply at any price below $1000. Novo Nordisk has had no commercial reason to cut list prices for insured patients, only for cash-pay segments where competition forced it.

European list prices for the same product are 75 to 90% lower. UK NHS contracts Wegovy at roughly £175 per month. Canadian list price is around CAD $400. The US price difference is structural, not cost based ^[4].

The cheapest legal path in 2026

Pick the branch that matches your situation.

If you have commercial insurance

1. Ask your prescriber whether your plan covers semaglutide for your indication (diabetes versus weight loss versus cardiovascular).
2. If covered, get the prescription filled and apply the manufacturer savings card. Expected cost: $25 per month for Ozempic, $0 to $225 for Wegovy.
3. If not covered for weight loss, ask the prescriber if you qualify under the cardiovascular indication (atherosclerotic disease plus BMI 27+). Many plans cover that.
4. If still not covered, move to NovoCare cash-pay for Wegovy at $499 per month, or to a different drug your plan does cover.

If you have Medicare

1. Ozempic and Rybelsus are covered Part D drugs for type 2 diabetes. Expect $0 to $100 monthly copays depending on plan.
2. Wegovy is covered only for cardiovascular risk reduction. Get the diagnosis documented. Expect $50 to $200 monthly copays.
3. The 2025 $2000 Part D out-of-pocket cap protects you on the high end.

If you have Medicaid

1. All state Medicaid plans cover Ozempic and Rybelsus for type 2 diabetes. Copay is typically $0 to $4.
2. About a dozen states cover Wegovy for weight loss. Check your state formulary.
3. Where not covered, ask your prescriber about patient assistance through NovoCare's PAP for low-income patients (separate from the $499 self-pay rate; this is a free-drug program for qualifying patients).

If you are uninsured

1. The NovoCare Wegovy self-pay program at $199 first month, $499 thereafter is the cheapest legal source of brand semaglutide. Sign up at novocare.com.
2. For type 2 diabetes, Ozempic at retail is $968. There is no manufacturer cash-pay rate. GoodRx may bring it to $800 to $850 at some pharmacies.
3. Patient-specific compounded semaglutide from a verified 503A pharmacy with a documented clinical need runs $200 to $400 per month. Verify the pharmacy is state-licensed and that your prescriber documents the clinical justification.
4. Apply for Novo Nordisk's Patient Assistance Program if your income is at or below 400% of the federal poverty level. Approved patients receive Wegovy or Ozempic free.

State by state pricing notes

Brand list prices do not vary by state. Insurance copays and Medicaid coverage do, but the rules are set by your plan, not your location. The few state-specific cost differences:

• Texas, Florida, Arizona: large telehealth markets, high competition among compounding pharmacies historically meant lower compounded prices ($200 to $250). Post-shortage, that arbitrage has narrowed.
• California, New York, Massachusetts: state-regulated insurance markets often require broader weight-loss drug coverage. Commercial copays for Wegovy run lower than national averages.
• Michigan, Idaho, Mississippi: state Medicaid programs cover Wegovy for weight loss with prior authorization.
• High-cost-of-living states: retail cash prices at pharmacy chains can run 5 to 10% above the national list price.

The variation is real but small compared to the differences between insurance, NovoCare, and compounded paths. Your situation matters more than your zip code.

Common questions about semaglutide cost

How much does semaglutide cost per month without insurance in 2026?

Brand Wegovy via NovoCare self-pay is $499 per month with a $199 first-month starter rate. Brand Ozempic at retail is around $968 per month. Patient-specific compounded semaglutide runs $200 to $400 per month where clinically justified.

What is the cheapest way to get semaglutide legally in 2026?

For commercial insurance holders, the manufacturer savings card brings Ozempic to $25 per month and Wegovy to $0 to $225 per month. For uninsured patients, NovoCare Wegovy at $499 per month is the cheapest brand option.

Does Medicare cover semaglutide for weight loss?

Medicare Part D covers Wegovy only when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and a BMI of 27 or higher. It does not cover Wegovy when prescribed for weight loss alone.

Does Medicaid cover semaglutide?

All state Medicaid programs cover Ozempic and Rybelsus for type 2 diabetes. About a dozen states cover Wegovy for weight loss, usually with prior authorization. Check your state's preferred drug list.

How much does Ozempic cost with the savings card?

With commercial insurance and the Ozempic savings card, the copay is $25 per month for up to 24 months, capped at $150 in savings per fill. Patients on government insurance are not eligible.

How much does Wegovy cost with the savings card?

The Wegovy savings card reduces commercial insurance copays by up to $225 per month, with an $1800 annual cap. If your commercial plan does not cover Wegovy, the card is not usable, and NovoCare cash-pay at $499 per month is the alternative.

Is compounded semaglutide still available in 2026?

Yes, but only as patient-specific compounded preparations with documented clinical justification, such as an excipient allergy or unusual dose. Mass-market compounded semaglutide is no longer permitted under FDA enforcement policy now that the shortage has resolved.

How much does Rybelsus cost per month?

Brand Rybelsus has a 2026 list price of about $1029 per month. With commercial insurance and the savings card, the typical copay is $25 to $100 per month. Medicare Part D coverage for type 2 diabetes brings copays into the $0 to $100 range.

Why is semaglutide so expensive in the United States?

US semaglutide prices reflect patent protection through the early 2030s, limited Medicare price negotiation until 2027 implementation, and demand that exceeds supply at any price below $1000. European list prices for the same drug are 75 to 90% lower.

Is semaglutide tax deductible?

Yes, when prescribed for a medical condition. Semaglutide costs qualify as itemized medical expenses subject to the 7.5% AGI threshold on a federal return. Save pharmacy receipts and any telehealth fees attributable to the prescription.

Does Tricare cover semaglutide?

Tricare covers Ozempic and Rybelsus for type 2 diabetes with prior authorization. Tricare covers Wegovy for chronic weight management when patients meet BMI and comorbidity criteria, with prior authorization. Coverage rules and copays follow the Tricare formulary tiers.

How long will insurance cover Wegovy?

Most commercial plans cover Wegovy as long as the patient continues to meet the plan's clinical criteria (typically BMI thresholds and prior authorization renewal every six to twelve months). Some plans cap coverage at 12 to 24 months; check your specific plan's policy.

What this article does not cover

This page is the pricing reference. Adjacent questions, like which specific telehealth provider is the best fit, how to file a prior authorization appeal, and which dose to start at, live on their own pages on this site. Use the search to find them. If you only remember one thing from this page, it is that the brand list price is rarely what you pay, and the cheapest legal path in 2026 depends entirely on what insurance, if any, you carry.